Emcure Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure of Key Performance Indicators (KPIs) under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018'.
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals has disclosed its audited Key Performance Indicators (KPIs) for FY25, FY24, and FY23, certified by R.B. Sharma and Co. The company's business mix has shifted towards international markets, with overseas revenue share rising from 46.84% (FY23) to 53.65% (FY25), while India share fell from 53.16% to 46.34%. EBITDA grew strongly to ₹15,312.6 million in FY25 from ₹12,767.8 million in FY24, with margins slightly improving to 19.23% from 19.01%. Profit after tax (PAT) jumped about 34% to ₹7,074.7 million, lifting PAT margin from 7.86% to 8.88%. Return on Capital Employed (RoCE) recovered to 22.04% in FY25, up from 19.37% in FY24, indicating improved capital efficiency.
This is a routine post-listing disclosure showing solid FY25 earnings growth, margin recovery, and stronger international business contribution. For shareholders, the rising exports share, double-digit PAT growth, and RoCE rebound to 22% are positive signals supporting the stock's growth narrative.